EUVIMEDEUVIMED entdecken
Crossref

Uptake of gonadotrophin‐releasing hormone agonists for prevention of premature ovarian insufficiency in women undergoing chemotherapy: an Australian single‐centre study

Felicity C Martin iD, Kelly-Anne Phillips, Nora Lee, Dimity Paul, Sarah Price, Genia Rozen, Catharyn Stern, Jing Sophia Xie, Wanda Cui iD

Internal Medicine Journal · 2025

DOI: 10.1111/imj.16564 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Internal Medicine Journal, 2025. Verfasst von Felicity C Martin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Primary Ovarian Insufficiency, Gonadotropin-Releasing Hormone, Goserelin, Neoplasms. Die Arbeit nennt 41 Literaturangaben. Gefördert von: Future Fertility, NHMRC, National Health and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Treatment‐related premature ovarian insufficiency (POI) can result in early‐onset menopause and infertility.

Aims

To assess the prevalence of goserelin use for POI prevention in women with cancer since it was listed by the Australian Pharmaceutical Benefits Scheme in 2018 for this indication.

Methods

This retrospective study included women aged 18–45 years who received curative‐intent alkylating chemotherapy for a malignancy between August 2020 and December 2022 at the Peter MacCallum Cancer Centre. The co‐primary end‐points were (i) documentation of a discussion with the patient regarding goserelin for POI prevention and (ii) prescription of goserelin for POI prevention prior to chemotherapy commencement.

Results

Sixty‐six patients were eligible. Fifty patients (76%) had a documented discussion regarding goserelin for POI prevention and 53 patients (80%) were prescribed goserelin for POI prevention. Nulliparous women were more likely to have a discussion regarding goserelin ( P = 0.004). Younger women, nulliparous women and those referred to a fertility service were more likely to have been prescribed goserelin for POI prevention ( P = 0.003, P = 0.001 and P = 0.002 respectively). Twenty‐one of 53 patients (40%) who received goserelin had the first dose administered ≥7 days before chemotherapy commencement.

Conclusion

One‐quarter of eligible patients did not have a documented discussion regarding goserelin, despite the negative consequences of POI. Efforts are needed to increase the discussion and use of goserelin in all premenopausal women regardless of their fertility interests and to ensure timely administration in those who choose to receive it.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Primary Ovarian InsufficiencyGonadotropin-Releasing HormoneGoserelinNeoplasmsAntineoplastic AgentsHumansFemaleAdultRetrospective StudiesAustraliaYoung AdultMiddle AgedAdolescent

Stichwörter der Autor:innen

cancerfertilitygonadotrophin‐releasing hormone agonistsgoserelininfertilitypremature ovarian insufficiency

Substanzen

Gonadotropin-Releasing HormoneGoserelinAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.
  • Centre for Epidemiology and Biostatistics, School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia.
  • Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • VCCC Consumer, Victorian Comprehensive Cancer Centre, Melbourne, Victoria, Australia.
  • Department of Obstetric Medicine, Royal Women's Hospital, Melbourne, Victoria, Australia.

ORCID-Profile: Felicity C Martin, Wanda Cui

Förderung

  • Future Fertility
  • NHMRC
  • National Health and Medical Research Council

Zitieren

APA

Martin, F. C., Phillips, K. A., Lee, N., Paul, D., Price, S., Rozen, G., Stern, C., Xie, J. S., & Cui, W. (2025). Uptake of gonadotrophin‐releasing hormone agonists for prevention of premature ovarian insufficiency in women undergoing chemotherapy: an Australian single‐centre study. Internal Medicine Journal. https://doi.org/10.1111/imj.16564

Vancouver

Martin FC, Phillips KA, Lee N, Paul D, Price S, Rozen G, et al. Uptake of gonadotrophin‐releasing hormone agonists for prevention of premature ovarian insufficiency in women undergoing chemotherapy: an Australian single‐centre study. Internal Medicine Journal. 2025. doi:10.1111/imj.16564

BibTeX
@article{Martin2025,
  author = {Martin, Felicity C and Phillips, Kelly-Anne and Lee, Nora and Paul, Dimity and Price, Sarah and Rozen, Genia and Stern, Catharyn and Xie, Jing Sophia and Cui, Wanda},
  title = {Uptake of gonadotrophin‐releasing hormone agonists for prevention of premature ovarian insufficiency in women undergoing chemotherapy: an Australian single‐centre study},
  journal = {Internal Medicine Journal},
  year = {2025},
  doi = {10.1111/imj.16564}
}
Kostenlos starten →